An immune-related gene pairs signature predicts overall survival in serous ovarian carcinoma

• Main Authors: Zhang L, Zhu P, Tong Y, Wang Y, Ma H, Xia X, Zhou Y, Zhang X, Gao F, Shu P
• Format: Article
• Language: English
• Published: Dove Medical Press 2019-08-01
• Series: OncoTargets and Therapy
• Subjects: serous ovarian carcinoma; prognosis; immune-related gene pairs
• Online Access: https://www.dovepress.com/an-immune-related-gene-pairs-signature-predicts-overall-survival-in-se-peer-reviewed-article-OTT

Liuyan Zhang,1,* Ping Zhu,2.* Yao Tong,3 Yuzhuo Wang,4 Haifen Ma,5 Xuefei Xia,6 Yu Zhou,6 Xingguo Zhang,6 Feng Gao,7,8 Peng Shu61Department of Obstetrics, Beilun People’s Hospital, Ningbo, People’s Republic of China; 2Department of Gynecology, CangZhou People’s Hospital, CangZhou, People’s Republic of China; 3Department of Molecular Biology and Genetics, College of Agriculture and Life Sciences, Cornell University, Ithaca, NY, USA; 4Department of Prenatal Diagnostic, CangZhou People’s Hospital, CangZhou, People’s Republic of China; 5Department of Pathology, Beilun People’s Hospital, Ningbo, People’s Republic of China; 6Department of Clinical Laboratory, Beilun People’s Hospital, Ningbo, People’s Republic of China; 7Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People’s Republic of China; 8Department of Molecular Diagnosis, Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Supported by National Key Clinical Discipline, Guangzhou, People’s Republic of China   *These authors contributed equally to this workCorrespondence: Peng ShuDepartment of Clinical Laboratory, Beilun People’s Hospital, Ningbo, People’s Republic of ChinaEmail [e-mail] GaoDepartment of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People’s Republic of ChinaEmail [e-mail] Background: Ovarian cancer has the highest death rate of all fatal gynecological cancers. Increasing evidence has depicted the correlation between serous ovarian carcinoma prognosis and immune signature. Therefore, the aim of this study is to develop a robust prognostic immune-related gene pairs (IRGPs) signature for estimating overall survival (OS) of HGSOC.Methods: Gene expression profiling and clinical information of serous ovarian carcinoma patients were derived from three public data sets, divided into training and validation cohorts. Immune genes significantly associated with prognosis were selected.Results: Among 1,534 immune genes, a 20 IRGPs signature was built which was significantly associated with OS in the training cohort (P=1.44×10−14,; hazard ratio [HR] =3.05 [2.26, 4.10]). In the validation datasets, the IRGPs signature significantly divided patients into high- vs low- risk groups considering their prognosis (P=4.30×10−3,; HR =1.48 [1.13, 1.95]) and was prognostic in multivariate analysis. Functional analysis showed that several biological processes, including EMT and TGF-β related pathways, enriched in the high-risk group. Macrophages M2 was significantly higher in the high-risk group compared with the low-risk group.Conclusion: We successfully constructed a robust IRGPs signature with prognostic values for serous ovarian carcinoma, providing new insights into post-operational treatment strategies.Keywords: serous ovarian carcinoma, prognosis, immune-related gene pairs